Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115447 | 0.82 | KMT2A (0.54) | KMT2AMEN1MAPTTP53ATM | |
| SCHEMBL18669191 | 0.73 | KMT2A (0.62) | KMT2AMEN1MAPTTP53ATM | |
| SCHEMBL15177630 | 0.68 | KMT2A (0.38) | KMT2AMEN1MAPTTP53ATM | |
| SCHEMBL633646 | 0.68 | KMT2A (0.53) | KMT2AMEN1MAPTTP53SLC22A12 | |
| SCHEMBL17827522 | 0.67 | KMT2A (0.45) | KMT2AMEN1 | |
| SCHEMBL6355968 | 0.67 | P2RX7 (0.67) | KMT2AMAPTP2RX7 | |
| SCHEMBL6356890 | 0.67 | P2RX7 (0.62) | KMT2AMEN1MAPTTP53PKM | |
| SCHEMBL18974311 | 0.65 | CA12 (0.67) | KMT2AMEN1MAPTTP53ATM | |
| SCHEMBL15233079 | 0.65 | KMT2A (0.50) | KMT2AMEN1MAPTTP53ATM | |
| SCHEMBL26530778 | 0.65 | KMT2A (0.80) | KMT2AMEN1MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| EP-2419426-B1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | H1-3, CHRM2, TBL3 | KMT2A 2219/4885MEN1 564/4885MAPT 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.